drugset / Trial / NCT01969851

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

NCT01969851

Phase 2 Completed 55 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

SP0966 is an exploratory study to investigate safety and efficacy of Lacosamide (LCM) in children with epilepsy syndromes associated with generalized seizures. LCM will be added to current antiepileptic treatment.

Timeline

Start
2014-02-13
Primary completion
2018-04-10
Completion
2018-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 4 mg/kg Oral
Subject Lacosamide Other / unclassified 200 mg Oral

Indications